Sander Wuyts, PhD 🧬
@swuyts.bsky.social
Helping scientists find the epitope specificity of their T-cell receptors at @immunewatch.bsky.social (www.immunewatch.com)
Scientist on an entrepreneurial journey
PhD in bioinformatics and microbiology
Ex-Bork (EMBL) and Lebeer lab
Scientist on an entrepreneurial journey
PhD in bioinformatics and microbiology
Ex-Bork (EMBL) and Lebeer lab
Finding the putative target of a TCR is hard!
But I am really excited to see that innovative cancer therapy companies like Obsidian Therapeutics are getting some real value out of using our database + machine learning algorithm.
But I am really excited to see that innovative cancer therapy companies like Obsidian Therapeutics are getting some real value out of using our database + machine learning algorithm.
November 24, 2025 at 9:26 AM
Finding the putative target of a TCR is hard!
But I am really excited to see that innovative cancer therapy companies like Obsidian Therapeutics are getting some real value out of using our database + machine learning algorithm.
But I am really excited to see that innovative cancer therapy companies like Obsidian Therapeutics are getting some real value out of using our database + machine learning algorithm.
Blown away by the quantity and quality of questions received yesterday during our webinar for bioinformaticians on “how to annotate the antigen specificity of a TCR repertoire”.
I might be biased but this level of engagement is definitely a +1 for bioinformaticians 😀
I might be biased but this level of engagement is definitely a +1 for bioinformaticians 😀
February 27, 2025 at 2:57 PM
Blown away by the quantity and quality of questions received yesterday during our webinar for bioinformaticians on “how to annotate the antigen specificity of a TCR repertoire”.
I might be biased but this level of engagement is definitely a +1 for bioinformaticians 😀
I might be biased but this level of engagement is definitely a +1 for bioinformaticians 😀